OBJECTIVE: Elite controllers are a rare subset of HIV-1-infected individuals who maintain HIV-1 RNA concentrations in plasma below the lower limit of quantification of clinical assays (<20-50 copies/ml) in the absence of antiretroviral therapy. Here, we examine to what extent elite controllers also control infection of the central nervous system (CNS). DESIGN: We analysed paired cerebrospinal fluid (CSF) and plasma samples using a highly sensitive assay for HIV-1 RNA quantification. METHODS: We analysed 28 CSF samples and 27 concurrent plasma samples from 14 elite controllers with the highly sensitive single-copy assay (SCA) that allows for HIV-1 RNA quantification down to less than one copy of HIV-1 RNA per millilitre. RESULTS: Three samples were excluded because of internal standard failure. HIV-1 RNA was detected in only five of 26 CSF samples compared with 14 of 26 plasma samples (P = 0.02), with a median of 0.2 (range, 0.1-6) copies/ml in CSF compared with 0.8 (range, 0.1-189 copies/ml) in plasma (P < 0.0001). CONCLUSION: HIV-1 RNA could not be detected in CSF in most elite controllers using the highly sensitive SCA, and when detected, it was at significantly lower frequencies and concentrations than in plasma. Elite controllers thus control HIV-1 in the CNS very well. Whether the infrequent and small amounts of HIV-1 RNA in the CSF reflect production from a local reservoir or virion exchange between the blood and the CSF is uncertain.
OBJECTIVE: Elite controllers are a rare subset of HIV-1-infected individuals who maintain HIV-1 RNA concentrations in plasma below the lower limit of quantification of clinical assays (<20-50 copies/ml) in the absence of antiretroviral therapy. Here, we examine to what extent elite controllers also control infection of the central nervous system (CNS). DESIGN: We analysed paired cerebrospinal fluid (CSF) and plasma samples using a highly sensitive assay for HIV-1 RNA quantification. METHODS: We analysed 28 CSF samples and 27 concurrent plasma samples from 14 elite controllers with the highly sensitive single-copy assay (SCA) that allows for HIV-1 RNA quantification down to less than one copy of HIV-1 RNA per millilitre. RESULTS: Three samples were excluded because of internal standard failure. HIV-1 RNA was detected in only five of 26 CSF samples compared with 14 of 26 plasma samples (P = 0.02), with a median of 0.2 (range, 0.1-6) copies/ml in CSF compared with 0.8 (range, 0.1-189 copies/ml) in plasma (P < 0.0001). CONCLUSION:HIV-1 RNA could not be detected in CSF in most elite controllers using the highly sensitive SCA, and when detected, it was at significantly lower frequencies and concentrations than in plasma. Elite controllers thus control HIV-1 in the CNS very well. Whether the infrequent and small amounts of HIV-1 RNA in the CSF reflect production from a local reservoir or virion exchange between the blood and the CSF is uncertain.
Authors: J B Hubert; M Burgard; E Dussaix; C Tamalet; C Deveau; J Le Chenadec; M L Chaix; E Marchadier; J L Vildé; J F Delfraissy; L Meyer Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: Joel N Blankson; Justin R Bailey; Seema Thayil; Hung-Chih Yang; Kara Lassen; Jun Lai; Shiv K Gandhi; Janet D Siliciano; Thomas M Williams; Robert F Siliciano Journal: J Virol Date: 2006-12-06 Impact factor: 5.103
Authors: Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker Journal: J Virol Date: 2008-06-18 Impact factor: 5.103
Authors: Sophie Grabar; Hana Selinger-Leneman; Sophie Abgrall; Gilles Pialoux; Laurence Weiss; Dominique Costagliola Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks Journal: J Virol Date: 2008-10-22 Impact factor: 5.103
Authors: Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948
Authors: Irini Sereti; Roy M Gulick; Sonya Krishnan; Stephen A Migueles; Adrian Palfreeman; Veronique Touzeau-Römer; Waldo H Belloso; Sean Emery; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731
Authors: Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: Clementine Wallet; Marco De Rovere; Jeanne Van Assche; Fadoua Daouad; Stéphane De Wit; Virginie Gautier; Patrick W G Mallon; Alessandro Marcello; Carine Van Lint; Olivier Rohr; Christian Schwartz Journal: Front Cell Infect Microbiol Date: 2019-10-24 Impact factor: 5.293
Authors: Anupama Ganesh; Donna Lemongello; Evelyn Lee; Julia Peterson; Bridget E McLaughlin; April L Ferre; Geraldine M Gillespie; Dietmar Fuchs; Steven G Deeks; Peter W Hunt; Richard W Price; Serena S Spudich; Barbara L Shacklett Journal: AIDS Res Hum Retroviruses Date: 2016-05-02 Impact factor: 2.205
Authors: Shelli F Farhadian; Hetal Mistry; Tobias Kirchwey; Jennifer Chiarella; Rachela Calvi; Michelle Chintanaphol; Payal Patel; Marie L Landry; Kevin Robertson; Serena S Spudich Journal: Open Forum Infect Dis Date: 2019-12-14 Impact factor: 3.835